Jubilant Life shares fall on USFDA warning letter

Shares in Jubilant Life Sciences Ltd fell as much as 6.9 per cent on Wednesday after US health regulators issued a warning letter to the company, citing "significant violations" of manufacturing standards at its facility in Canada.

The U.S. Food and Drug Administration may hold drug approvals until Jubilant HollisterStier General Partnership takes necessary corrective steps, Jubilant said in a statement.

Other bigger Indian companies such as Dr. Reddy's Laboratories Ltd, Ranbaxy Laboratories LTd, Sun Pharmaceutical Industries Ltd and Aurobindo Pharma have all received regulatory warning letters on compliance over the last four years.

The company said its on-going manufacturing, distribution and sale of products would not be affected by the warning letter, and it plans to respond to the drug regulator on or before March 15.

Shares in Jubilant Life Sciences, which has a market value of about $548.5 million, fell 4.25 percent to 178 rupees. They earlier touched a low of 173 rupees. The broader market was up 0.67 percent.

EDITORIAL OF THE DAY

  • Finance minister has been pragmatic in exempting FIIs from MAT claims

    Good sense has finally prevailed in the government, with finance minister Arun Jaitley announcing the income-tax officials will exempt overseas funds

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Amita Sharma

Centre set to scrap 60:40 norm for NITs

A committee set up by the ministry of human resource ...

Zehra Naqvi

If you bend, you won’t break

There’s an ancient exercise about a green, supple new branch ...

Gautam Gupta

Bring on the Benares brigade

It was in 2003 when I first started work and ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture